CD8A and glioblastoma: Chisato Yokota et al. developed a vaccine based on Wilms’ tumor gene 1 (WT1) peptides, which activated NK cells by inducing WT1-specific CD8+ T cells and CD4+ T cells, as well as NK cell infiltration into tumors in the GL261 mouse glioblastoma model [52].